COMP <GO>
WST vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
West Pharmaceutical Services Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: WST 5
— JNJ 8
■ METRIC PARITY
LAST: $412.62 (-0.97%) • MKT CAP: $29.32B
options-implied-move
7.20%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
7.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 67.90% | -32.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 25.50% | -7.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 18.5x | +16.20 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 2.97% | -1.37 | JNJ | /fcf-yield <GO> |
| Operating Margin | 19.00% | 34.70% | -15.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 28.50% | -12.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 6.00% | +0.30 | WST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 0.00% | +0.21 | WST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 5.59 | +13.47 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | WST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.3 | 60.4 | +14.98 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 23.0x | +32.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $662.49B | -$633.17B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | JNJ REV | WST GROSS % | JNJ GROSS % | WST FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $94.19B | 35.9% | 67.9% | $468.9M | $19.70B |
| FY 2024 | $2.89B | $88.82B | 34.5% | 69.1% | $276.4M | $19.84B |
| FY 2023 | $2.95B | $85.16B | 44.0% | 44.0% | $643.8M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
JNJ // BETA 1.08